The market leader in AI-powered clinical trial optimisation and automation
Trusted By
About Us
Our vision is to set the benchmark as the leading platform for predicting, simulating, and optimising clinical trials worldwide.
Opyl is a new generation, Australian digital health company that specialises in the application of artificial intelligence to enhance clinical trial design and forecast outcomes, thereby empowering clinical researchers, biopharmaceutical corporations, and medical investors to understand and improve trial design, development, and delivery.
Solutions
Clinical trials are the foundation of medical progress. However, 90% of trials fail, with less than a 30% success rate, and 60% failing due to inadequate design. The primary challenge is navigating vast, complex datasets to make informed decisions..
Opyl’s AI model, TrialKey, is trained using data from over 468,429 trials, simulating trial scenarios over 100,000 times to provide data-driven recommendations for critical trial elements through robust biostatistical validation. With over 92% accuracy in predicting trial phase completion, TrialKey helps researchers navigate the complexities of trial design more effectively.
Technology
Our platform utilities over 468,429 trials, 114,925 conditions, 2.69 billion patients, and 608,400,000 data points, and integrates AI/M/L with biostatistical modelling, analysing structured and unstructured data to simulate and refine clinical trial strategies.
Investor Relations
Access ASX announcements, periodic reports, presentations, and other investor resources.
Featured In
